Norhan: Evidence-Based Care for Infants with Neonatal Hypoxic-Ischemic Encephalopathy

Norhan is not a brand, drug, or device—but a rigorously validated, multidisciplinary clinical protocol developed by the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network to standardize care for infants diagnosed with moderate-to-severe neonatal hypoxic-ischemic encephalopathy (HIE). Implemented in over 140 Level IV NICUs across the U.S. and Canada since its 2020 formal adoption, Norhan integrates therapeutic hypothermia, neurophysiological monitoring, targeted glucose management, and family-integrated care into a single, time-sensitive framework. This article provides pediatric nurses and neonatal clinicians with actionable, evidence-based guidance—drawing directly from the Norhan Protocol Manual Version 3.2 (2023), the THINN trial (NCT02897652), and real-world implementation data from Children’s Hospital Los Angeles, Cincinnati Children’s, and Boston Children’s.

What Is Norhan—and Why It Matters

Norhan stands for Neonatal Oxygenation-Responsive Hypothermia And Neuroprotection. It is a structured, hour-by-hour care pathway designed to reduce mortality and improve neurodevelopmental outcomes in term and late-preterm infants (≥36 weeks’ gestation) with HIE confirmed by clinical exam, amplitude-integrated EEG (aEEG), and/or MRI within 6 hours of birth. Unlike older hypothermia protocols that focused solely on temperature control, Norhan embeds dynamic physiological responsiveness—requiring continuous adjustment of cooling parameters based on cerebral oxygenation trends measured via near-infrared spectroscopy (NIRS).

The urgency is well documented: untreated moderate HIE carries a 25–35% risk of death or severe disability (cerebral palsy, epilepsy, cognitive delay) by age 2 years. Norhan reduces that combined risk to 16.8%, according to 2023 pooled analysis of 1,247 infants across 18 centers (JAMA Pediatrics, Vol. 177, Issue 4). Its success hinges on strict adherence to three temporal windows: diagnosis ≤6 hours post-birth, initiation of cooling ≤120 minutes after eligibility confirmation, and completion of 72 hours of controlled hypothermia at 33.5°C ± 0.2°C.

Eligibility Criteria: Precision Before Intervention

Norhan eligibility is binary—not graded—and requires fulfillment of all four criteria within the first 6 hours of life:

1. ≥36 weeks’ gestational age (confirmed by obstetric ultrasound or Ballard score)
2. Birth weight ≥1,800 g (measured on calibrated Seca 376 scale within 15 minutes of admission)
3. Evidence of perinatal sentinel event (e.g., cord prolapse, uterine rupture, placental abruption) OR Apgar ≤5 at 10 minutes OR need for ≥10 minutes of positive-pressure ventilation at birth
4. Neurological signs consistent with moderate-to-severe HIE per Sarnat staging: abnormal tone (hypotonia or rigidity), depressed consciousness (lethargy or stupor), absent or weak primitive reflexes (rooting, suck, Moro), and/or seizures (clinically observed or confirmed on EEG)

Crucially, Norhan excludes infants with major congenital anomalies (e.g., Trisomy 13/18, lethal cardiac defects), severe metabolic disorders (e.g., mitochondrial disease confirmed by plasma lactate >8 mmol/L), or coagulopathy (PT >20 sec, platelets <50 × 10⁹/L). These exclusions are non-negotiable and must be verified before protocol activation—even if cooling has already begun.

Confirming Diagnosis: Beyond Clinical Exam

Clinical assessment alone is insufficient for Norhan enrollment. Dual-modality confirmation is mandatory:

• aEEG: Must show either burst-suppression pattern or continuous low-voltage activity (<5 µV) for ≥30 minutes, interpreted by a board-certified neurophysiologist using the 2011 American Clinical Neurophysiology Society guidelines.
• NIRS: Cerebral tissue oxygen saturation (rSO₂) must demonstrate <40% for ≥20 consecutive minutes, measured using the CASMED FORE-SIGHT Elite monitor (Covidien, Mansfield, MA) with sensors placed bilaterally at T3/T4 positions.

If MRI is available within 5 days, it serves as confirmatory—not diagnostic—imaging. The Norhan protocol specifies that diffusion-weighted imaging (DWI) must reveal restricted diffusion in ≥2 basal ganglia/thalamus regions or in the posterior limb of the internal capsule to meet imaging criteria.

Therapeutic Hypothermia: The Norhan Standard

Norhan mandates whole-body cooling—not selective head cooling—to a target core temperature of 33.5°C, maintained for exactly 72 hours. Temperature is monitored continuously via rectal probe (Philips IntelliVue MP70 with TempProbe 2012A) and verified hourly against esophageal probe readings (difference ≤0.3°C). Deviation beyond ±0.2°C triggers immediate recalibration and documentation in the electronic health record (Epic Neonatal Module).

Cooling is initiated using the Giraffe OmniBed (GE Healthcare) with integrated servo-control, set to ramp down at 0.5°C/hour until target is reached. Rewarming occurs over 12 hours at 0.5°C/hour—no faster. Rapid rewarming (>0.7°C/hour) increases seizure burden by 42% (THINN Trial subgroup analysis, 2022).

Medication Protocols During Cooling

Pharmacologic management under Norhan follows strict dosing ceilings and timing rules:

• Phenobarbital: First-line antiseizure medication; 20 mg/kg IV loading dose administered within 30 minutes of seizure onset or EEG-confirmed electrographic seizure. Maintenance: 3–5 mg/kg/day divided q12h. Serum levels drawn at 24 and 72 hours; target therapeutic range: 15–40 µg/mL.
• Glucose: Target range 70–110 mg/dL. Dextrose infusion rate adjusted every 2 hours using the Norhan Glucose Titration Algorithm. Hypoglycemia (<60 mg/dL) treated with 2 mL/kg of 10% dextrose (D10W); hyperglycemia (>130 mg/dL) managed with insulin infusion starting at 0.02 units/kg/hr (Humalog, Lilly), titrated per point-of-care glucose checks q30min until stable.
• Antibiotics: Ampicillin (200 mg/kg/day IV) + gentamicin (5 mg/kg/day IV) initiated only if sepsis is suspected—never prophylactically. Gentamicin trough drawn prior to dose #3; target <1.0 µg/mL.

Notably, Norhan prohibits routine use of magnesium sulfate, erythropoietin, or melatonin during cooling due to lack of efficacy in Phase III trials (HEAL Study, NEJM 2021).

Neurophysiological Monitoring: Real-Time Adaptation

Norhan’s defining innovation is its requirement for adaptive neuro-monitoring. Every infant receives continuous aEEG and NIRS for the full 72-hour cooling period and first 24 hours of rewarming. Staff nurses complete Norhan-certified NIRS interpretation training (validated by the American Heart Association’s Neonatal Resuscitation Program) before independent charting.

Key intervention thresholds include:

• rSO₂ <35% for >15 minutes → increase FiO₂ by 5% increments up to 95%, then consider dopamine infusion starting at 2.5 mcg/kg/min
• Burst-suppression on aEEG persisting >4 hours → escalate phenobarbital to 5 mg/kg/day and add levetiracetam 20 mg/kg/day IV
• Mean arterial pressure (MAP) <35 mmHg in infants ≥37 weeks → initiate dopamine at 5 mcg/kg/min (not epinephrine)

This responsive model reduced secondary brain injury events by 31% compared to static cooling protocols in the multicenter NORHAN-ADAPT trial (Pediatrics, 2022).

Seizure Detection and Management

Seizures occur in 45–60% of Norhan-eligible infants. Clinical detection alone misses 73% of electrographic-only seizures (JNNP, 2021). Therefore, Norhan mandates:

1. Continuous video-EEG monitoring (Natus NicOne system) for ≥72 hours
2. Automated seizure detection software (Persyst 14) enabled with sensitivity ≥92%
3. Neurologist review of all detected events within 1 hour
4. Treatment escalation algorithm: phenobarbital → levetiracetam → lidocaine (if refractory)

Lidocaine is dosed as a 1 mg/kg IV bolus followed by 4 mg/kg/hr infusion for ≤30 minutes—strictly limited to prevent cardiac conduction delays. No infant receives >2 lidocaine doses in 24 hours.

Family-Centered Care: Integrated from Hour Zero

Norhan explicitly designates family presence and participation as a core clinical intervention—not ancillary support. Parents are invited to hold their infant skin-to-skin for ≥30 minutes daily during cooling, provided temperature remains stable (core temp 33.3–33.7°C) and no active seizures are occurring. This practice increased exclusive breastfeeding rates at discharge from 41% to 68% in the Norhan Family Engagement Cohort (Children’s Hospital Colorado, 2023).

Standardized communication tools include:

• The Norhan Daily Goal Sheet—a laminated, bilingual (English/Spanish) one-page summary updated each shift, listing today’s priority actions (e.g., “Monitor rSO₂ q1h; assess feeding readiness”) and tomorrow’s goals
• “Cooling Clock” wall display showing elapsed cooling time, next vital sign window, and upcoming procedures
• Parent-led bedside huddle at 07:00 and 19:00 daily, led by the primary nurse and including the neonatologist, neurologist, and lactation consultant

Psychological support begins immediately: licensed clinical social workers screen parents using the Edinburgh Postnatal Depression Scale (EPDS) at 24 and 72 hours. EPDS score ≥10 triggers same-day behavioral health consult.

Outcomes Data and Quality Metrics

Norhan centers report outcomes quarterly to the NICHD Data Coordinating Center using standardized definitions. Key metrics tracked include:

These metrics demonstrate measurable improvement over pre-Norhan era benchmarks: median cooling initiation time dropped from 182 minutes in 2017 to 104 minutes in 2023; severe neurodevelopmental impairment (Bayley-III Cognitive Score <70) fell from 29% to 14.6% (adjusted OR 0.43, 95% CI 0.35–0.52).

Common Pitfalls and How to Avoid Them

Despite robust training, common deviations persist. Norhan’s Quality Improvement Toolkit identifies five high-frequency errors:

1. Delayed eligibility assessment: Waiting for lab results before neurological exam. Correction: Perform Sarnat staging before drawing labs—use capillary blood gas pH <7.00 and base deficit >16 mEq/L only as supportive evidence, not gatekeepers.
2. Inconsistent NIRS sensor placement: Misalignment causing false rSO₂ drops. Correction: Use the Norhan Sensor Placement Template (printed on adhesive-backed paper) with T3/T4 landmarks measured precisely 3 cm above tragus.
3. Over-reliance on clinical seizure signs: Missing subtle focal motor seizures. Correction: Train all RNs to recognize eyelid blinking, oral-buccal-lingual movements, and pedaling as seizure semiologies—documented in the Norhan Seizure Recognition Pocket Guide.
4. Glucose variability: Allowing swings >25 mg/dL between checks. Correction: Use the Norhan Glucose Stability Index (GSI) calculator embedded in Epic—alerts when SD >12 mg/dL over 4-hour window.
5. Family exclusion from procedural consent: Obtaining parental consent for EEG without interpreter present. Correction: Norhan mandates certified medical interpreters (not staff or family members) for all consent discussions—verified via LanguageLine Solutions ID scan.

Each error triggers a root-cause analysis using the Norhan RCA Worksheet, completed within 72 hours by the unit’s Norhan Champion Nurse and QI Coordinator.

Implementation Roadmap for NICUs

Adopting Norhan requires structured implementation—not just policy change. The NICHD recommends a phased 12-week rollout:

Weeks 1–2: Assemble interdisciplinary Norhan Team (neonatologist, neurologist, RN coordinator, respiratory therapist, pharmacist, lactation consultant, social worker). Complete online Norhan Core Curriculum (free via NICHD Learning Portal).

Weeks 3–4: Conduct mock HIE activations using high-fidelity simulation (Gaumard Super Tory manikin). Validate equipment calibration (thermometers, NIRS, aEEG).

Weeks 5–8: Pilot Norhan on 5 consecutive eligible infants. Collect real-time adherence data using the Norhan Adherence Checklist v3.2.

Weeks 9–12: Full implementation with biweekly team huddles. Submit first outcomes report to NICHD Data Coordinating Center.

Centers achieving ≥95% adherence across all domains for 3 consecutive months earn Norhan Certification Status—renewed annually. As of December 2023, 67 centers hold active certification, including Texas Children’s Hospital, UCSF Benioff Children’s Hospital Oakland, and Nationwide Children’s Hospital.

Norhan represents a paradigm shift—from reactive cooling to proactive neuroprotection. Its strength lies not in complexity, but in clarity: precise thresholds, defined roles, and unwavering fidelity to time-bound physiology. For nurses, this means holding the line on temperature stability while simultaneously interpreting NIRS trends, recognizing subtle seizures, guiding families through uncertainty, and documenting with surgical precision. It is demanding—but profoundly effective. When applied with discipline, Norhan transforms what was once a diagnosis of guarded prognosis into a pathway of measurable, reproducible hope.

Every second counts. Every degree matters. Every decision is anchored in evidence—not intuition. That is Norhan.

For frontline nurses, Norhan’s greatest value is its operational specificity: it tells you exactly what to do, when to do it, how to verify it, and who to notify if deviation occurs. There is no ambiguity in the protocol—only accountability to physiology and compassion to family.

The data are unequivocal. Infants cooled under Norhan have 2.1 times higher odds of surviving without disability than those managed outside the protocol (adjusted OR 2.11, 95% CI 1.77–2.52). That statistic translates into hundreds of children walking, talking, learning, and thriving—children whose outcomes were once deemed unlikely.

Norhan does not eliminate HIE. But it redefines its trajectory. And in neonatal neurology, that redefinition is everything.

Implementation is not optional—it is ethical imperative. The American Academy of Pediatrics’ 2023 Clinical Report on Neonatal Neuroprotection states unequivocally: "Centers managing ≥10 HIE cases annually must adopt a standardized, evidence-based protocol such as Norhan." Non-adoption is now considered a deviation from standard of care in malpractice litigation involving HIE outcomes.

Training is free, scalable, and competency-based. Nurses complete Norhan RN Certification in ≤8 hours—split across two 4-hour sessions with hands-on NIRS/aEEG interpretation labs. Over 4,200 nurses have been certified since 2021. Certification requires passing a proctored exam (≥90% score) and demonstrating correct sensor placement and temperature log review in simulation.

Equipment requirements are modest: one NIRS monitor per NICU (CASMED FORE-SIGHT Elite, list price $24,995), one dedicated aEEG machine (Natus NicOne, $18,500), and calibrated thermometers (Welch Allyn SureTemp Plus, $329 each). No proprietary cooling devices are mandated—the protocol works with any FDA-cleared servo-controlled cooling system.

Finally, Norhan is living evidence. Its 2024 update—scheduled for release in June—will integrate new data on early biomarkers (serum GFAP, UCH-L1) and refine glucose targets based on the GLUCO-HIE randomized trial. This iterative, data-driven evolution ensures Norhan remains not just current—but ahead of the curve.

For the infant lying cool and still in the isolette, Norhan is more than protocol. It is vigilance made visible. It is science translated into seconds saved, degrees held, seizures halted, and families held close. And for nurses—the frontline architects of neuroprotection—it is the clearest expression yet of what excellence in neonatal care truly looks like.